In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates

Veterinary Microbiology

Volumn 174, Issue 3-4, 2014, Pages 514-522

  Liu, Xiaoqiang ^a   Lazzaroni, Caterina ^b   Aly, Sherine A ^c   Thungrat, Kamoltip ^b   Boothe, Dawn M ^b  

^a NORTHWEST A F UNIVERSITY   (China)

^b AUBURN UNIVERSITY   (United States)

^c Assiut University Faculty of Medicine   (Egypt)

Author keywords

Ciprofloxacin; Escherichia coli; Pradofloxacin; Resistance mechanism; Stepwise mutation

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; MARBOFLOXACIN; MEROPENEM; ORBIFLOXACIN; PRADOFLOXACIN; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ESCHERICHIA COLI PROTEIN; QUINOLONE DERIVATIVE;

ACRB GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CANINE MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; GAPA GENE; GENE FUNCTION; GYRA GENE; IN VITRO SELECTION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PARC GENE; PHENOTYPE; POINT MUTATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOXS GENE; UROPATHOGENIC ESCHERICHIA COLI; ANIMAL; DOG; DOG DISEASES; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PHYSIOLOGY; URINARY TRACT INFECTIONS; VETERINARY;

ESCHERICHIA COLI;

ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASES, TYPE I; DOG DISEASES; DOGS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 84924079885     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2014.10.011     Document Type: Article

References (36)

1. Aly S.A., Debavalya N., Suh S.J., Oryazabal O.A., Boothe D.M. Molecular mechanisms of antimicrobial resistance in fecal Escherichia coli of healthy dogs after enrofloxacin or amoxicillin administration. Can. J. Microbiol. 2012, 58:1288-1294.
2. Beyer R., Pestova E., Millichap J.J., Stosor V., Noskin G.A., Peterson L.R. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob. Agents Chemother. 2000, 44:798-801.
3. Biswas S., Maggi R.G., Papich M.G., Breitschwerdt E.B. Molecular mechanisms of Bartonella henselae resistance to azithromycin, pradofloxacin and enrofloxacin. J. Antimicrob. Chemother. 2010, 65:581-582.
4. Buffet-Bataillon S., Le Jeune A., Le Gall-David S., Bonnaure-Mallet M., Jolivet-Gougeon A. Molecular mechanisms of higher MICs of antibiotics and quaternary ammonium compounds for Escherichia coli isolated from bacteraemia. J. Antimicrob. Chemother. 2012, 67:2837-2842.
5. Chen Y.M., Wright P.J., Lee C.S., Browning G.F. Uropathogenic virulence factors in isolates of Escherichia coli from clinical cases of canine pyometra and feces of healthy bitches. Vet. Microbiol. 2003, 94:57-69.
6. CLSI Performance Standards for Antimicrobial Susceptiblity Testing; Twenty-Second Informational Supplement. (ISBN 1-56238-785-5). CLSI Document M100-S22 2012, Clinical Laboratory Standards Institute, Wayne, PA, USA.
7. Cooke C.L., Singer R.S., Jang S.S., Hirsh D.C. Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. J. Am. Vet. Med. Assoc. 2002, 220:190-192.
8. Drlica K. A strategy for fighting antibiotic resistance. ASM News 2001, 67:27-33.
9. Drlica K., Malik M. Fluoroquinolones: action and resistance. Curr. Top. Med. Chem. 2003, 3:249-282.
10. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 1997, 61:377-392.
11. Gibson J.S., Cobbold R.N., Kyaw-Tanner M.T., Heisig P., Trott D.J. Fluoroquinolone resistance mechanisms in multidrug-resistant Escherichia coli isolated from extraintestinal infections in dogs. Vet. Microbiol. 2010, 146:161-166.
12. Hartmann A., Krebber R., Daube G., Hartmann K. Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration. J. Vet. Pharmacol. Ther. 2008, 31:87-94.
13. Jacoby G.A. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 2005, 41(Suppl. 2):S120L 126.
14. Keeney D., Ruzin A., McAleese F., Murphy E., Bradford P.A. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J. Antimicrob. Chemother. 2008, 61:46-53.
15. Komp Lindgren P., Karlsson A., Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. 2003, 47:3222-3232.
16. Korber-Irrgang B., Wetzstein H.G., Bagel-Trah S., Hafner D., Kresken M. Comparative activity of pradofloxacin and marbofloxacin against coagulase-positive staphylococci in a pharmacokinetic-pharmacodynamic model based on canine pharmacokinetics. J. Vet. Pharmacol. Ther. 2012, 35:571-579.
17. Lautenbach E., Metlay J.P., Mao X., Han X., Fishman N.O., Bilker W.B., Tolomeo P., Wheeler M., Nachamkin I. The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patients. Clin. Infect. Dis. 2010, 51:280-285.
18. Lees P. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat. J. Vet. Pharmacol. Ther. 2013, 36:209-221.
19. Litster A., Moss S., Honnery M., Rees B., Edingloh M., Trott D. Clinical efficacy and palatability of pradofloxacin 2.5% oral suspension for the treatment of bacterial lower urinary tract infections in cats. J. Vet. Intern. Med. 2007, 21:990-995.
20. Liu X., Boothe D.M., Jin Y., Thungrat K. In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States. World J. Microbiol. Biotechnol. 2013, 29:347-354.
21. Liu X., Boothe D.M., Thungrat K., Aly S. Mechanisms accounting for fluoroquinolone multidrug resistance Escherichia coli isolated from companion animals. Vet. Microbiol. 2012, 161:159-168.
22. Miller P.F., Gambino L.F., Sulavik M.C., Gracheck S.J. Genetic relationship between soxRS and mar loci in promoting multiple antibiotic resistance in Escherichia coli. Antimicrob. Agents Chemother. 1994, 38:1773-1779.
23. Mueller R.S., Stephan B. Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial. Vet. Dermatol. 2007, 18:144-151.
24. Pan X.S., Ambler J., Mehtar S., Fisher L.M. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 1996, 40:2321-2326.
25. Pestova E., Millichap J.J., Noskin G.A., Peterson L.R. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 2000, 45:583-590.
26. Ravanel N., Gestin B., Maurin M. In vitro selection of fluoroquinolone resistance in Brucella melitensis. Int. J. Antimicrob. Agents 2009, 34:76-81.
27. Sanchez S., McCrackin Stevenson M.A., Hudson C.R., Maier M., Buffington T., Dam Q., Maurer J.J. Characterization of multidrug-resistant Escherichia coli isolates associated with nosocomial infections in dogs. J. Clin. Microbiol. 2002, 40:3586-3595.
28. Schink A.K., Kadlec K., Hauschild T., Brenner Michael G., Dorner J.C., Ludwig C., Werckenthin C., Hehnen H.R., Stephan B., Schwarz S. Susceptibility of canine and feline bacterial pathogens to pradofloxacin and comparison with other fluoroquinolones approved for companion animals. Vet. Microbiol. 2013, 162:119-126.
29. Shaheen B.W., Boothe D.M., Oyarzabal O.A., Wang C., Johnson C.M. Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats. Am. J. Vet. Res. 2011, 72:25-32.
30. Shaheen B.W., Nayak R., Foley S.L., Kweon O., Deck J., Park M., Rafii F., Boothe D.M. Molecular characterization of resistance to extended-spectrum cephalosporins in clinical Escherichia coli isolates from companion animals in the United States. Antimicrob. Agents Chemother. 2011, 55:5666-5675.
31. Silley P., Stephan B., Greife H.A., Pridmore A. Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. J. Antimicrob. Chemother. 2007, 60:999-1003.
32. Silley P., Stephan B., Greife H.A., Pridmore A. Bactericidal properties of pradofloxacin against veterinary pathogens. Vet. Microbiol. 2012, 157:106-111.
33. Wetzstein H.G. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob. Agents Chemother. 2005, 49:4166-4173.
34. White D.G., Goldman J.D., Demple B., Levy S.B. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J. Bacteriol. 1997, 179:6122-6126.
35. Yang S., Clayton S.R., Zechiedrich E.L. Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. J. Antimicrob. Chemother. 2003, 51:545-556.
36. Yasufuku T., Shigemura K., Shirakawa T., Matsumoto M., Nakano Y., Tanaka K., Arakawa S., Kinoshita S., Kawabata M., Fujisawa M. Correlation of overexpression of efflux pump genes with antibiotic resistance in Escherichia coli Strains clinically isolated from urinary tract infection patients. J. Clin. Microbiol. 2011, 49:189-194.